Early bring of potential cancer treatment vaccine using Russian mRNA technology to Vietnam

NDO - By signing an official document with the Russian Direct Investment Fund, VNVC is making efforts to soon access the potential cancer vaccine using Russia's modern mRNA technology, recently announced, and bring it to Vietnam.

On the evening of May 10 (Vietnam time), in Moscow (Russia), under the witness of General Secretary To Lam and Russian President Vladimir Putin, Vietnam Vaccine Company (VNVC) and the Russian Direct Investment Fund (RDIF) signed a strategic cooperation agreement in the field of scientific research and technology transfer for the production of vaccines and advanced biological drugs.

The document signed between the Russian Direct Investment Fund (RDIF) and VNVC Vaccine Company was presented in the presence of the two heads of Vietnam and Russia during the event within the framework of the official visit to the Russian Federation by General Secretary To Lam from May 8 to 11, on the occasion of the 80th anniversary of Victory Day in the Great Patriotic War and the 75th anniversary of the establishment of Vietnam-Russia diplomatic relations.

According to the cooperation agreement between RDIF and VNVC, the two sides will discuss to establish a foundation for deep cooperation on high technology in the field of biomedicine, focusing on research, investment, technology transfer and trade of biological drugs and high-tech vaccines. In particular, VNVC's top expectation is to soon bring in a potential cancer treatment vaccine based on the leading modern mRNA technology that Russia has recently announced.

In addition to this important cooperation document, VNVC also signed a cooperation agreement with the Gamaleya National Research Center for Epidemiology and Microbiology on scientific research cooperation and biotechnology development. VNVC also signed an agreement with the Russian pharmaceutical group Binnopharm.

Mr. Kirill Dmitriev, Special Representative of the President of Russia for Foreign Economic and Investment Affairs, General Director of the Russian Direct Investment Fund (RDIF), representing Russia, exchanged cooperation documents with Mr. Ngo Chi Dung, Chairman and General Director of VNVC Vaccine Company, in the presence of Russian President V. Putin and General Secretary To Lam. (Photo: THONG NHAT)

Immediately after signing, VNVC will begin scientific exchange activities with scientists from many Russian research institutes and high-level hospitals to receive technology transfer for research, testing and production of vaccines using mRNA technology.

In particular, research and development of vaccine production according to the "complete, closed cycle" model in Vietnam, focusing on pharmaceutical products that are Binnopharm's strengths, along with other important Russian pharmaceutical products, with a special focus on the field of high-tech cancer diagnosis and treatment.

Previously, in December 2024, the National Medical Research Center for Radiology under the Russian Ministry of Health announced that the country was researching and developing a potential lung cancer vaccine, produced using advanced mRNA technology.

According to the cooperation agreement between RDIF and VNVC, potential Russian mRNA technology vaccines will be brought to Vietnam by VNVC soon from the early stage of clinical trials so that patients have the opportunity to access more of the world's leading modern solutions with a very high success rate after treatment.

In addition, Russia's implementation of clinical trials of biological drugs and advanced technology vaccines in Vietnam also helps the registration, licensing and commercialization of products to be more convenient and faster as soon as good results are achieved.

According to the cooperation agreement, Russia's potential mRNA technology vaccine will be brought to Vietnam by VNVC soon from the early stage of clinical trials.

Kirill Dmitriev, Special Representative of the President of Russia for Foreign Economic and Investment Affairs and General Director of the Russian Direct Investment Fund (RDIF), said that Russia and Vietnam have many conditions for investment cooperation and technology transfer, especially in the fields of biomedicine and healthcare. During the Covid-19 pandemic, Vietnam is one of the countries that has approved the use of Russia's Sputnik V Covid-19 vaccine.

“The cooperation framework we announced today will play an important role in enhancing scientific exchanges and technology transfer between the two countries to develop pioneering healthcare products,” Kirill Dmitriev emphasized.

Highly appreciating the cooperative relationship with prestigious Russian agencies, Mr. Ngo Chi Dung, Chairman of the Board of Directors and CEO of VNVC Vaccine Company, affirmed that this is an important milestone, opening up opportunities for Vietnam to access and test vaccines on the most advanced mRNA technology that Russia is promoting research and development.

With this agreement, VNVC not only participates in clinical trial research and product commercialization, but can also manufacture at the VNVC Vaccine and Biological Products Factory in Long An.

According to Mr. Ngo Chi Dung, in the context that Vietnam records hundreds of thousands of new cases and deaths from cancer each year, this important cooperation agreement will open up new opportunities for cancer treatment with the first vaccine in the country, contributing to cost savings and improving the quality of life for people. This event also affirms the strong efforts of Vietnam's healthcare sector, of which VNVC is the representative, in international cooperation on science and technology and investment in developing modern vaccine production capacity for Vietnam under the direction of Resolution 57 of the Politburo.

Source: https://nhandan.vn/som-mang-vaccine-dieu-tri-ung-thu-tiem-nang-cong-nghe-mrna-cua-nga-ve-viet-nam-post878922.html